ERBB2 and ovarian carcinoma: Serial work from numerous endeavors and The Cancer Genome Atlas (TCGA) seeking for potential therapeutic opportunities have unraveled a massive repertoire of candidate cancer prognostic signatures and drug targets that gives rise to an amount of immuno- and targeted-therapeutic strategies represented by microsatellite instability as parameters for immune checkpoint inhibition therapy [1], trastuzumab targeting HER-2 in HER-2 positive cancer [2,3], Olaparib targeting PARP1 in BRCA1/BRCA2 mutant ovarian cancer and etc. [4].